Neisseria Meningitidis Clinical Trial
Official title:
A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants
The purpose of this study is to assess the feasibility of a single priming dose of NeisVac-C in infants (at either 4 or 6 months of age), as determined by immune response.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
| Completed |
NCT01090453 -
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
|
Phase 2 | |
| Completed |
NCT00454987 -
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
|
Phase 4 | |
| Completed |
NCT00891176 -
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
|
Phase 3 | |
| Completed |
NCT01839188 -
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
|
Phase 3 | |
| Completed |
NCT01553279 -
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
|
Phase 3 | |
| Completed |
NCT00263653 -
Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197
|
Phase 3 | |
| Completed |
NCT00772070 -
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
|
Phase 2 | |
| Completed |
NCT00129116 -
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
|
Phase 2 | |
| Completed |
NCT00127855 -
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
|
Phase 2 | |
| Completed |
NCT00871338 -
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
|
Phase 2 | |
| Completed |
NCT00700635 -
Dose Comparison Study of Menactra® in US Children
|
Phase 2 | |
| Completed |
NCT00326118 -
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
|
Phase 3 | |
| Completed |
NCT01730391 -
Neisseria Meningitidis Burden of Disease Study
|
N/A | |
| Completed |
NCT00197795 -
Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
|
Phase 2 | |
| Completed |
NCT00289783 -
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
|
Phase 3 | |
| Completed |
NCT00444951 -
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
|
Phase 3 | |
| Completed |
NCT00258700 -
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine
|
Phase 3 | |
| Completed |
NCT03419533 -
Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
|
||
| Completed |
NCT01978093 -
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
|
Phase 3 |